A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
- Author:
Dae-Won LEE
1
;
Bhumsuk KEAM
;
Keun Seok LEE
;
Jin-Hee AHN
;
Joohyuk SOHN
;
Jin Seok AHN
;
Moon Hee LEE
;
Jee Hyun KIM
;
Kyung Eun LEE
;
Hyo Jung KIM
;
Si-Young KIM
;
Yeon Hee PARK
;
Chan-Young OCK
;
Kyung-Hun LEE
;
Sae-Won HAN
;
Sung-Bae KIM
;
Young Hyuck IM
;
Hyun Cheol CHUNG
;
Do-Youn OH
;
Seock-Ah IM
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2023;55(2):523-530
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.
Materials and Methods:Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient’s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.
Results:A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2–positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).
Conclusion:This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.
